G protein-coupled receptor for catecholamines that couples to both G(s) and G(i) proteins, leading to either activation or inhibition of adenylate cyclase and cAMP-dependent pathway, respectively (PubMed:10188996, PubMed:2570461, PubMed:8641219). The rank order of potency for physiological agonists is norepinephrine > epinephrine (PubMed:10188996, PubMed:2570461, PubMed:8641219). Involved in the regulation of thermogenesis and lipolysis in brown and white adipose tissue, after coupling to G(s) proteins and stimulation of the cAMP-PKA axis (By similarity).
Also activates lipolytic process by coupling to G(i) proteins and consequent initiation of the ERK1/2 MAP kinase cascade (PubMed:10207024). Participates in relaxation of the blood vessels and the urinary bladder (PubMed:10188996). Also mediates negative inotropic effects in cardiomyocytes through activation of an NO synthase pathway and subsequent increase in cGMP levels, possibly involving G(i/o) protein-mediated coupling (PubMed:9769330)
Interacts with ARRDC3
Expressed mainly in adipose tissues
Click a pathway to open the interactive Reactome viewer.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to ADRB3, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 15
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT03902080 | Overactive Bladder | Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | PHASE3 | COMPLETED |
| NCT03583372 | Overactive Bladder | An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). | PHASE3 | COMPLETED |
| NCT03049462 | Polycystic Ovary Syndrome | The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists | PHASE1 | RECRUITING |
| NCT02381106 | Pregnancy Complications | The ADRB3 Receptor in Pregnancy | N/A | SUSPENDED |
| NCT04103450 | Overactive Bladder | Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia | PHASE3 | COMPLETED |
| NCT04626960 | Overactive Bladder | ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients | N/A | COMPLETED |
| NCT05491525 | Neurogenic Detrusor Overactivity | A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC | PHASE2, PHASE3 | RECRUITING |
| NCT02599480 | Hypertrophy, Left Ventricular | Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure | PHASE2 | COMPLETED |
| NCT05634174 | Obesity, Prediabetes | ADRB3 Signaling Pathway in Human Adipose Tissue | PHASE1 | ACTIVE_NOT_RECRUITING |
| NCT02862886 | Pregnancy | Study of the Effect of Beta-3 Adrenergic Receptor Agonists on Oxidative Stress and Signalling Pathways Implicated in Remodelling of the Uteroplacental Space: Experimental in Vitro Approach on Myometrial Tissue Explants | NA | COMPLETED |